arXivDaily arXiv每日学术速递 周一至周五更新
arXiv 2209.01655stat.ME
收藏

DROID:肿瘤药物开发中优化剂量的剂量范围方法

DROID: Dose-ranging Approach to Optimizing Dose in Oncology Drug Development

Beibei Guo, Ying Yuan

摘要:

在靶向治疗时代,人们越来越关注基于几十年前为化疗开发的“越多越好”范式的肿瘤药物的开发。最近,美国食品药品监督管理局(FDA)启动了Optimus项目,以改革肿瘤药物开发中的剂量优化和剂量选择范式。为了适应这种模式的转变,我们提出了一种剂量范围的方法来优化剂量(DROID)的肿瘤学试验与靶向药物。DROID利用了成熟的剂量范围研究框架,该框架已被常规用于开发非肿瘤药物数十年,并将其与已建立的肿瘤剂量发现设计相结合,以优化肿瘤药物的剂量。Droid由两个无缝连接的阶段组成。在第一阶段,患者按顺序入组并适应性分配研究剂量,以确定治疗剂量范围(TDR),定义为具有可接受毒性和疗效特征的剂量范围,以及推荐的II期剂量组(RP 2S)。在第二阶段,将患者随机分配至RP 2S中的剂量,以评估剂量-反应关系并确定最佳剂量。模拟研究表明,DROID大大优于传统方法,为有效优化靶向肿瘤药物的剂量提供了新的范例。

英文摘要:

In the era of targeted therapy, there has been increasing concern about the development of oncology drugs based on the "more is better" paradigm, developed decades ago for chemotherapy. Recently, the US Food and Drug Administration (FDA) initiated Project Optimus to reform the dose optimization and dose selection paradigm in oncology drug development. To accommodate this paradigm shifting, we propose a dose-ranging approach to optimizing dose (DROID) for oncology trials with targeted drugs. DROID leverages the well-established dose-ranging study framework, which has been routinely used to develop non-oncology drugs for decades, and bridges it with established oncology dose-finding designs to optimize the dose of oncology drugs. DROID consists of two seamlessly connected stages. In the first stage, patients are sequentially enrolled and adaptively assigned to investigational doses to establish the therapeutic dose range (TDR), defined as the range of doses with acceptable toxicity and efficacy profiles, and the recommended phase 2 dose set (RP2S). In the second stage, patients are randomized to the doses in RP2S to assess the dose-response relationship and identify the optimal dose. The simulation study shows that DROID substantially outperforms the conventional approach, providing a new paradigm to efficiently optimize the dose of targeted oncology drugs.

机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。

↑